Spiraling fears over the coronavirus and the multiplication of virus outbreaks across the globe have impacted the worldwide economy, threatened supply chains, and caused severe stock market declines and disruptions in the...more
3/13/2020
/ Coronavirus/COVID-19 ,
Disclosure Requirements ,
Infectious Diseases ,
MD&A Statements ,
PSLRA ,
Regulation S-K ,
Securities and Exchange Commission (SEC) ,
Securities Exchange Act ,
Securities Fraud ,
Securities Litigation ,
Supply Chain
On February 21, 2018, the Securities and Exchange Commission (“SEC”) published interpretive guidance on public company cybersecurity disclosures. While the new guidance confirms the SEC’s intensified focus on cybersecurity...more
On December 15, 2016, the United States Court of Appeals for the Eleventh Circuit affirmed the dismissal of a securities class action against Galectin Therapeutics Inc., a Georgia-based biotechnology company. The suit...more
12/21/2016
/ Disclosure Requirements ,
Financial Markets ,
Pharmaceutical Industry ,
Public Offerings ,
Publicly-Traded Companies ,
Rule 10(b) ,
Securities ,
Securities Exchange Act ,
Securities Fraud ,
Securities Litigation ,
Securities Violations ,
Stock Promoters ,
Stocks ,
Third-Party Agents
SEC’s Factual Allegations -
On September 9, 2016, the Securities and Exchange Commission (“SEC”) filed a complaint against RPM International Inc. (“RPM”) and its General Counsel and Chief Compliance Officer, alleging the...more